Modalities beyond small molecules

From PROTAC^®s to peptides

Innovative therapeutic approaches are expanding the horizons of drug discovery, incorporating small molecules into groundbreaking modalities such as PROTAC^®s, ADCs and peptide-based structures. Our medicinal chemists bring extensive expertise to these emerging fields, offering tailored chemical solutions to advance your drug development process.

A peptide-like ligand binding to a protein

Design and synthesis of degraders, ADCs and peptide libraries

Nuvisan offers a comprehensive suite of chemistry services across various advanced therapeutic modalities:

Proteolysis targeting chimeras (PROTAC^®s)

Optimisation of exit vectors, linker length and composition for oral bioavailability.
Digital Life Sciences support, including:
- Binder design for POIs/E3 ligases
- Structure-based and de novo linker optimisation
- Ternary complex prediction
Proven track record in delivering preclinical PROTAC^® compounds efficiently.

Antibody–drug conjugates (ADCs)

Advanced linker optimisation to reduce systemic exposure and limit toxicity.

Peptide-based drug development

Parallel peptide synthesis in 48/96-well reactors for sequences up to 20 amino acids
Design and incorporation of non-natural amino acids
Specialised expertise in:
- Peptide stapling and cyclic peptide design.
- 18F-labelling for advanced applications.
- SAR generation and PK optimisation for peptide-based small molecules.

These capabilities allow Nuvisan to deliver precise and innovative solutions, driving progress in your drug discovery programs.